Rocket Lab Scraps $3.6 Billion Bridge Loan After $1.94 Billion Equity Raise for Iridium Deal

Rocket Lab finalized a $1.944 billion equity offering to fund its ~$8 billion Iridium acquisition, retiring a $3.6 billion bridge loan before drawing on it.

Rocket Lab has closed the books on a $1.944 billion at-the-market equity offering, issuing roughly 29.3 million new shares and eliminating the need for a $3.6 billion bridge loan that Deutsche Bank and Wells Fargo had arranged to back its acquisition of Iridium Communications.

The capital raise, finalized on September 15, funds the cash portion of a deal valued at approximately $8 billion that was unveiled in June. By retiring the bridge facility before drawing on it, Rocket Lab avoids the carrying costs of short-term debt and locks in its capital structure well ahead of closing. Iridium, for its part, amended its existing credit agreement on Tuesday to adjust $1.775 billion in term loans to the coming change of control.

The transaction still needs sign-off from Iridium shareholders, who vote on September 24, as well as clearance from the FCC. U.S. antitrust waiting periods have already lapsed. Management expects the deal to close in mid-2027.

CFO Adam Spice framed the purchase as the "final piece" of a strategy to build an integrated space operator combining launch vehicles and satellite infrastructure under one roof. Iridium's 2025 results — $871.7 million in revenue and $495 million in operating EBITDA — underpin the financial case for a combination that has already cleared antitrust review.

A Deliberate Choice to Dilute Rather Than Borrow

The decision to fund the deal with equity instead of a short-term credit line carries a clear trade-off. Existing holders absorb dilution, but the combined company sidesteps the leverage that a multibillion-dollar bridge facility would have imposed. For a deal of this size, that reads as a management team willing to grow aggressively without stretching its balance sheet.

The market has not taken the news in stride. Since reporting second-quarter results about a month ago, Rocket Lab shares have retreated 21%, with the equity issuance itself likely adding to the pressure. The stock trades at EUR 55.20, roughly 9% below its 50-day moving average of EUR 60.91 — evidence that upbeat corporate announcements have yet to reverse the medium-term downtrend that took hold after those quarterly figures. Thirty-day volatility sits at 46%.

Launch Cadence and Recurring Revenue

Operationally, Rocket Lab keeps delivering. On September 11, the company completed its 16th Electron launch of the year, sending an Earth-observation satellite for an undisclosed customer into a 500-kilometer orbit — the 95th Electron mission overall. Days earlier, on September 2, the 94th flight, "Owl Around The World," lifted off for Japanese client Synspective, which has 16 more missions booked through 2030. That kind of repeat business functions as a ballast for a launch provider.

Hardware development continues in parallel. In early September, Rocket Lab unveiled IMM Apex, a new generation of space-grade solar cells that dispense with germanium, weigh 40% less and convert sunlight at 31.5% efficiency — a detail that underscores the vertical integration running through the company.

Defense Tailwinds and Analyst Support

The broader sector got a jolt on Tuesday when the U.S. Space Force publicly confirmed for the first time the operational use of weapons systems in orbit. Air Force Secretary Troy Meink referred to "kinetic and non-kinetic means" without elaborating. Under the Golden Dome program for space-based missile defense, 20 agreements worth up to $3.2 billion were awarded to twelve companies in April, with a demonstration target set for 2028.

Analyst Rob Stallard of Vertical Research Partners lists Rocket Lab among the potential beneficiaries, alongside HawkEye 360, Planet Labs and Firefly Aerospace. Rocket Lab already holds a $266 million missile-defense contract for twelve launches, plus a smaller $12 million award for a Space Data Network.

On the research front, Brian Gesuale of Raymond James initiated coverage with an Outperform rating and an $80 price target.

The Bet Behind the Balance Sheet

The Iridium purchase stands as the largest wager in Rocket Lab's history, and the funding method suggests management is treating the risk seriously. Whether it pays off will hinge less on the equity raise itself than on whether Iridium and the Neutron rocket live up to expectations. Until the shareholder vote and regulatory approvals land, investors should brace for choppy trading on the road to a mid-2027 close.